Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 1997

View Archived Issues

Grape seed proanthocyanidins compared to other antioxidants in vitro and in vivo

Antioxidants/hypolipidemics from ADIR

Merck KGaA describes PDE IV inhibitors

Azko Nobel discloses antiglucocorticoids

WF-10917: new immunosuppressant from Fujisawa

Xytronyx's immunotherapy shows positive preclinical results

Endothelin antagonists disclosed by BASF

Signal describes agents that block transcription factor activation

Arzneimittelwerk describes new anticonvulsants

Potent, orally active ACAT inhibitors from Sankyo

Yamasa describes cognition-enhancing agents

Genzyme Transgenics and NCI collaborate to expand cancer vaccine trials

Avigen granted patent on high-yield AAV production for gene therapy

Sch-56592 in phase II trials for fungal infections

Cel-Sci initiates clinical trial of Multikine in Israel

Eletriptan enters phase III trials

Gliatech's ADCON-L to recieve expedited review by FDA

Clinical results from international comparative study of olanzapine and haloperidol

BioChem Pharma: Q1 1997 highlights

Biogen: Q1 1997 highlights

DepoTech: Q1 1997 highlights

Dura Pharmaceuticals: Q1 1997 highlights

Immunex: Q1 1997 highlights

Stockbrokers Society issues research report on Maxim Pharmaceuticals

MGI Pharma: Q1 1997 highlights

Roche: Q1 1997 highlights

Synsorb Biotech recieves U.S. patent for the use of Synsorb Pk

ImmuCell's TravelGAM to enter field study in cooperation with U.S. Navy

Final FDA approval for Faulding's acyclovir injection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...